{
    "clinical_study": {
        "@rank": "88902", 
        "arm_group": [
            {
                "arm_group_label": "H. pylori no treatment", 
                "arm_group_type": "No Intervention", 
                "description": "Observational group, with clinical and platelet count follow-up"
            }, 
            {
                "arm_group_label": "H. pylori triple therapy", 
                "arm_group_type": "Experimental", 
                "description": "Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether eradication of Helicobacter pylori\n      infection is effective in the improvement of platelet counts in children and adolescents\n      with chronic ITP."
        }, 
        "brief_title": "Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Immune Thrombocytopenic Purpura", 
            "Helicobacter Pylori Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic", 
                "Helicobacter Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Helicobacter pylori infection has been associated with Immune Thrombocytopenic Purpura\n      (ITP), and there is scientific evidence for the investigation and treatment of this\n      bacterium for adult patients with ITP. However, in children this causal association is not\n      clear, with few published studies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  clinical diagnosis of chronic immune thrombocytopenic purpura\n\n          -  children and adolescents up to 20 years\n\n        Exclusion Criteria:\n\n          -  known hypersensitivity to any of the drugs\n\n          -  recent treatment for H. pylori eradication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730352", 
            "org_study_id": "08/56706-0"
        }, 
        "intervention": {
            "arm_group_label": "H. pylori triple therapy", 
            "description": "Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.", 
            "intervention_name": "H. pylori triple therapy", 
            "intervention_type": "Drug", 
            "other_name": [
                "Triple therapy for H. pylori", 
                "H. pylori eradication therapy", 
                "Pyloripac"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Clarithromycin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "immune thrombocytopenic purpura", 
            "chronic immune thrombocytopenic purpura", 
            "secondary immune thrombocytopenic purpura", 
            "Helicobacter pylori infection", 
            "Helicobacter pylori gastritis", 
            "children", 
            "adolescents"
        ], 
        "lastchanged_date": "November 20, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "04021-001"
                    }, 
                    "name": "Federal University of Sao Paulo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "01401-000"
                    }, 
                    "name": "Centro de Hematologia de Sao Paulo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "05614-040"
                    }, 
                    "name": "Hospital Estadual Infantil Darcy Vargas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "01221-020"
                    }, 
                    "name": "Irmandade da Santa Casa de Misericordia se Sao Paulo"
                }
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial", 
        "overall_official": {
            "affiliation": "Federal University of Sao Paulo", 
            "last_name": "Elisabete Kawakami, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: Agencia Nacional de Vigilancia Sanitaria (ANVISA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Responders: Complete Response (CR), persistent elevation of platelet count to >150\u00d7109/L; Partial Response (PR), elevation between 20 and 30\u00d7109/L above the baseline values, but between 50 and 149\u00d7109/L; No Responders: any of the above categories.", 
            "measure": "platelet response", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730352"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of S\u00e3o Paulo", 
            "investigator_full_name": "Elisabete Kawakami", 
            "investigator_title": "Professor, PhD MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Federal University of S\u00e3o Paulo", 
        "sponsors": {
            "collaborator": {
                "agency": "Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Federal University of S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}